Jennifer Drake

Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.

B. Williams, J. Zaia, A. Krieg, 2012, The Journal of infectious diseases.

Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants

Anna M. Acosta, P. Frankel, J. Zaia, 2022, iScience.

MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.

I. Aldoss, J. Zaia, J. Longmate, 2017, Blood.

Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.

I. Aldoss, Jeffrey S. Miller, J. Zaia, 2016, The Lancet. Haematology.

Cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic hematopoietic stem cell transplantation: viremia, immunogenicity and survival outcomes in a randomised phase 1b trial

I. Aldoss, Jeffrey S. Miller, J. Zaia, 2015, The Lancet. Haematology.

Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial

A. Sette, P. Frankel, J. Zaia, 2022, The Lancet Microbe.